PVLA · Palvella Therapeutics, Inc. · Executive Compensation
$129.96
+7.00 (+5.69%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$1.77B
Shares
14.41M
Volume · Oct 20
45.14K
Avg daily vol (3M)
212.9K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,358,952 |
| Thomas Bures | Senior Vice President and Chief Financial Officer | $729,037 |
| Shane Olwill | Former Senior Vice President and Chief Development Officer | $705,445 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $2,062,843 |
| Ahmed Mousa | Senior Vice President and Chief Business Officer | $963,967 |
| Thomas Bures | Senior Vice President and Chief Financial Officer | $944,191 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,692,917 |
| Tim Demuth | M.D., Ph.D.\ Senior Vice President and Chief Medical Officer | $1,246,462 |
| Hitto Kaufmann | Senior Vice President and Chief Scientific Officer | $876,757 |
| Thomas Bures | Senior Vice President and Chief Financial Officer | $772,644 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,538,829 |
| Hitto Kaufmann | Senior Vice President and Chief Scientific Officer | $548,636 |
| Thomas Bures | Vice President, Finance | $514,544 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,593,598 |
| Hitto Kaufmann | Ph.D.\ Senior Vice President and Chief Scientific Officer | $1,101,279 |
| Louis Matis | M.D.\ \ Chief Development Officer | $759,021 |
| Thomas Bures | Vice President, Finance | $476,680 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $2,621,008 |
| Louis Matis | M.D.\ \ Chief Development Officer | $1,124,169 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Matthew Pauls | Class I director | Appointed | 2026-06-30 |
| Todd C. Davis | Class III director | Appointed | 2026-06-16 |
| John Doux, M.D. | Class III director | Appointed | 2026-06-16 |
| George M. Jenkins | Class III director | Appointed | 2026-06-16 |
| John Doux, M.D. | Class III director | Appointed | 2026-04-13 |
| Tom Bures | Acting General Counsel | Resigned | 2024-12-16 |
| Tom Bures | Senior Vice President and Chief Financial Officer | Resigned | 2024-12-16 |
| Stephen Yoder | President and Chief Executive Officer | Resigned | 2024-12-16 |
| Thomas Bures | Senior Vice President and Chief Financial Officer | Terminated | 2024-12-16 |
| Jeffrey Martini | Chief Scientific Officer | Appointed | 2024-12-16 |
| Stephen Yoder | President and Chief Executive Officer | Terminated | 2024-12-16 |
| Kathleen Goin | Chief Operating Officer | Appointed | 2024-12-16 |
| Matthew Korenberg | Chief Financial Officer | Appointed | 2024-12-16 |
| George M. Jenkins | Chairman of the Board | Appointed | 2024-12-16 |
| Wesley H. Kaupinen | Chief Executive Officer, Founder, President and Director | Appointed | 2024-12-16 |
| Todd C. Davis | Director | Appointed | 2024-12-16 |
| Elaine J. Heron | Director | Appointed | 2024-12-16 |
| George M. Jenkins | Director | Appointed | 2024-12-16 |
| Tadd S. Wessel | Director | Appointed | 2024-12-16 |
| Maya R. Said | Director | Resigned | 2024-12-16 |
| Wesley H. Kaupinen | Director | Appointed | 2024-12-16 |
| Peter Kiener | Director | Resigned | 2024-12-16 |
| Matthew Sherman | Director | Resigned | 2024-12-16 |
| Ann Barbier | Director | Resigned | 2024-12-16 |
| Michael Richman | Director | Resigned | 2024-12-16 |
Leadership
- Wesley H. Kaupinen CEO, Board Member
- George M. Jenkins Chairman, Board Member
- James Geraghty Chairman
- Matthew E. Korenberg CFO
- Matthew Korenberg CFO
- Kathleen Goin COO
- Jeffrey Martini CTO
- Jeffrey Martini, Ph.D. CTO
- Christopher Kiritsy Board Member
- Elaine J. Heron Board Member
- Elaine J. Heron, Ph.D. Board Member
- John Doux Board Member
- John Doux, M.D. Board Member
- Matthew L. Sherman, M.D. Board Member
- Matthew Pauls Board Member
- Michael Richman Board Member
- Peter Kiener, D.Phil. Board Member
- Stephen S. Yoder Board Member
- Tadd S. Wessel Board Member
- Todd C. Davis Board Member
Key facts
CIK
1583648
CUSIP
697947109
13F (30d)
13 filings
13 filers
Visit website
Investor relations